Lale SUSAN KARAKIŞ, Engin TURKGELDİ, Hüseyin KIYAK, Neşe YÜCEL

Abnormal First and Second Trimester Maternal Serum Marker Levels For Aneuploidy Screening and Adverse Pregnancy Outcomes

To investigate if there is an association between pregnancy complications and abnormal maternal serum analytes used forfirst trimester screening (FTS) and second trimester screening (STS) for aneuploidy.More than two hundred three pregnant women who had FTS or STS for Down's syndrome who presented between July2009 and January 2010 were included. First trimester maternal levels of PAPP-A and free hCG or 2nd trimester maternallevels of AFP, uE3 and hCG were compared between healthy pregnancies and those with preeclampsia, intrauterinegrowth retardation, intrauterine fetal death or oligohydramnios.PAPP-A levels less than 0.4 MoMs were related with elevated preeclampsia and fetal growth retardation risk. AFP levelsover 2.5 MoMs were related with all adverse outcomes evaluated in the study including preeclampsia, fetal growthretardation, intrauterine fetal demise and oligohydramnios. While uE3 levels below 0.5 MoM were found to be related withhigher preeclampsia incidence, elevated 2nd trimester hCG levels over 3.0 MoMs were associated with fetal growthretardation. No significant relationship could be established between low 1st trimester free hCG levels (less than 0.5MoMs) and any of the adverse outcomes.First and 2nd trimester serum analytes for Down syndrome screening are significantly linked with pregnancy complications.However, because their sensitivity and positive predictive values are low, these analytes are not shown to be effective inthe screening of pregnancy complications when used alone.

PDF

___

1. Walker JJ. Pre-eclampsia. Lancet. 2000; 356: 1260-1265.

2. Gaccioli F, Aye ILMH, Sovio U, CharnockJones DS, Smith GCS. Screening for fetal growth restriction using fetal biometry combined with maternal biomarkers. Am J Obstet Gynecol 2018; 218: S725-S737.

3. Krause TG, Christens P, Wohlfahrt J, Lei U, Westergaard T, Norgaard-Pedersen B, et al. Second-trimester maternal serum alphafetoprotein and risk of adverse pregnancy outcome. Obstet Gynecol 2001; 97: 277-282.

4. Gagnon A, Wilson RD, Audibert F, et al Society of Obstetricians and Gynaecologists of Canada Genetics Committee. Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can 2008; 30: 918-949.

5. Dugoff L. Society for Maternal-Fetal Medicine. First- and second-trimester maternal serum markers for aneuploidy and adverse obstetric outcomes. Obstet Gynecol 2010; 115: 1052-1061.

6. Dugoff L, Hobbins JC, Malone FD, Porter TF, Luthy D, Comstock CH, et al. Firsttrimester maternal serum PAPP-A and freebeta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (The FASTER Trial). Am J Obstet Gynecol 2004; 191: 1446-1451.

7. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin Summary, Number 222. Obstet Gynecol 2020; 135: 1492-1495.

8. Yaron Y, Cherry M, Kramer RL, et al. Secondtrimester maternal serum marker screening: maternal serum alpha-fetoprotein, beta-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol 1999; 181: 968-967.

9. Dugoff L, Cuckle HS, Hobbins JC, et al. FaSTER Trial Research Consortium. Prediction of patient-specific risk for fetal loss using maternal characteristics and first- and second-trimester maternal serum Down syndrome markers. Am J Obstet Gynecol. 2008; 199: 290.

10. Spencer K, Cowans NJ, Nicolaides KH. Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia. Prenat Diagn 2008; 28: 7-10.

11. Krantz D, Goetzl L, Simpson JL, et al. First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. Association of extreme firsttrimester free human chorionic gonadotropinbeta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol 2004; 191: 1452-1458.

12. Huang T, Hoffman B, Meschino W, Kingdom J, Okun N. Prediction of adverse pregnancy outcomes by combinations of first and second trimester biochemistry markers used in the routine prenatal screening of Down syndrome. Prenat Diagn 2010; 30: 471-477.

13. Spencer K. Second-trimester prenatal screening for Down syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse outcome. Prenat Diagn 2000; 20: 652- 656.

14. Morris RK, Cnossen JS, Langejans M, et al. Serum screening with Down's syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and metaanalysis. BMC Pregnancy Childbirth 2008; 8: 33.

15. Chandra S, Scott H, Dodds L, Watts C, Blight C, Van Den Hof M. Unexplained elevated maternal serum alpha-fetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes. Am J Obstet Gynecol 2003; 189: 775-781.

16. Dugoff L, Hobbins JC, Malone FD, et al. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol. 2005; 106: 260-267.

17. Towner D, Gandhi S, El Kady D. Obstetric outcomes in women with elevated maternal serum human chorionic gonadotropin. Am J Obstet Gynecol 2006; 194: 1676-1682.

18. Onderoğlu LS, Kabukçu A. Elevated second trimester human chorionic gonadotropin level associated with adverse pregnancy outcome. Int J Gynaecol Obstet 1997; 56: 245-249.

19. Kowalczyk TD, Cabaniss ML, Cusmano L. Association of low unconjugated estriol in the second trimester and adverse pregnancy outcome. Obstet Gynecol 1998; 91: 396-400.

20. Sayin NC, Canda MT, Ahmet N, Arda S, Süt N, Varol FG. The association of triple-marker test results with adverse pregnancy outcomes in low-risk pregnancies with healthy newborns. Arch Gynecol Obstet 2008; 277: 47-53.

21. Schleifer RA, Bradley LA, Richards DS, Ponting NR. Pregnancy outcome for women with very low levels of maternal serum unconjugated estriol on second-trimester screening. Am J Obstet Gynecol 1995; 173: 1152-1156.

22. Spencer K, Yu CK, Cowans NJ, Otigbah C, Nicolaides KH. Prediction of pregnancycomplications by first-trimester maternal serum PAPP-A and free beta-hCG and withsecond-trimester uterine artery Doppler. Prenat Diagn 2005; 25: 949-953.

23. Elsandabesee D, Srinivas M, Kodakkattil S. The clinical value of combining maternal serum screening and uterine artery Doppler in prediction of adverse pregnancy outcome. J Obstet Gynaecol 2006; 26: 115-117.

24. Onwudiwe N, Yu CK, Poon LC, Spiliopoulos I, Nicolaides KH. Prediction of pre-eclampsia by a combination of maternal history, uterine artery Doppler and mean arterial pressure. Ultrasound Obstet Gynecol 2008; 32: 877-883.

25. Poon LC, Kametas NA, Maiz N, et al. Firsttrimester prediction of hypertensive disorders in pregnancy. Hypertension 2009; 53: 812-818.

26. Poon LC, Shennan A, Hyett JA, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet 2019; 145: 1-33.

27. Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH. Combined screening for preeclampsia and small for gestational age at 11-13 weeks. Fetal Diagn Ther 2013; 33: 16- 27.